The NM_000152.5: c.2417C>T variant in GAA is a missense variant predicted to cause substitution of threonine by methionine at amino acid 806 (p.Thr806Met). The variant was reported to be identified on 5 alleles in a cohort of 2372 individuals with limb girdle muscular dystrophy undergoing NGS panel sequencing (PMID: 39678382). One of those individuals, from Russia, is reported to have Pompe disease (Supplemental Table 4) and to be heterozygous for the variant; however, the full genotype and clinical information were not provided (insufficient evidence to apply PP4 or PM3). The highest population minor allele frequency in gnomAD v4.1.0. is 0.00155 (93/59992 alleles) in the Admixed American population, which is higher than the ClinGen LD VCEP's threshold (<0.001) for PM2_Supporting and lower than the threshold for BS1 (>0.005), and therefore none of the populations codes are met. The computational predictor REVEL gives a score of 0.435 which is below the threshold of 0.5, evidence that does not predict a damaging effect on GAA function. No impact on splicing is predicted by SpliceAI (BP4). There is a ClinVar entry for this variant (Variation ID: 252467). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for Pompe disease due to insufficient evidence. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): BP4. (Classification approved by the ClinGen Lysosomal Diseases VCEP on July 30, 2025).